Foundayo vs Mounjaro: Tablet and Injection Compared

If you are weighing up Foundayo vs Mounjaro, the core difference is simple to state: Foundayo (orforglipron) is a once-daily tablet, while Mounjaro (tirzepatide) is a weekly injection. But the two medicines also differ in how they work at the receptor level, and that shapes what to expect. This article compares them calmly, without hype in either direction.

This is information only, not medical advice. Both are prescription-only medicines, and a qualified prescriber is the person who decides whether any treatment is suitable for you.

Foundayo vs Mounjaro: the essentials at a glance

Both medicines belong to the broad family of incretin-based treatments — drugs that mimic hormones your gut releases after eating. Where they part company is in their chemistry and their delivery.

• Foundayo (orforglipron) — a non-peptide, small-molecule GLP-1 receptor agonist, designed to be swallowed as a daily tablet.
• Mounjaro (tirzepatide) — a peptide that activates both the GLP-1 and GIP receptors, given as a once-weekly injection.

To understand the tablet's design in more depth, see our companion article on how orforglipron works.

How each one works in the body

GLP-1 (glucagon-like peptide-1) is a hormone released after meals. It prompts the pancreas to release insulin when blood sugar rises, slows how fast the stomach empties, and acts on appetite centres in the brain so you feel full sooner. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also influences insulin and fat metabolism.

Mounjaro: a dual-receptor peptide

Tirzepatide activates both the GLP-1 and GIP receptors — this is why it is often described as a "dual agonist". Because it is a peptide (a small protein-like chain of amino acids), it would be broken down in the gut if swallowed, so it is injected under the skin once a week.

Foundayo: a single-receptor tablet

Orforglipron targets only the GLP-1 receptor, similar to semaglutide. Crucially, it is a small molecule made by chemical synthesis rather than a peptide, so it can survive digestion and be absorbed as a tablet — without the strict fasting rules that oral semaglutide requires. That is the headline appeal of the Foundayo vs Mounjaro comparison: a genuinely convenient oral option for people who dislike injections.

What the trial evidence suggests

Trial results are the fairest way to compare medicines, but you have to be careful comparing across different studies with different participants and durations.

For context, tirzepatide's SURMOUNT-1 trial produced average weight loss of around 21% at the top dose over roughly 72 weeks alongside lifestyle changes — among the strongest results seen for a weight-management medicine. Semaglutide 2.4 mg, a single GLP-1 agonist like orforglipron, produced around 15% in the STEP 1 trial.

Orforglipron's own phase 3 results are now published. In ATTAIN-1, a 72-week trial in 3,127 adults with obesity, or overweight with a weight-related condition, and no type 2 diabetes, published in the New England Journal of Medicine, the highest research dose produced average weight loss of 12.4% of body weight, compared with 0.9% on placebo, according to the UK Summary of Product Characteristics; the paper's primary analysis, which also counts results after people stopped treatment, gives 11.2% versus 2.1%. ATTAIN-2, published in The Lancet, also found significantly greater weight loss than placebo in adults who also have type 2 diabetes. Both trials compared orforglipron with placebo, not with Mounjaro, so there is no head-to-head result. We keep a general summary on our home page and track the research on our development page. Beware of anyone quoting precise head-to-head figures as if the two had been tested directly against each other in the same trial.

Tablet vs injection: the practical differences

For many people, the day-to-day experience matters as much as the numbers.

• Route: Foundayo is a daily tablet; Mounjaro is a weekly injection using a pre-filled pen.
• Frequency: Once daily versus once weekly. Some prefer the routine of a daily pill; others prefer a single weekly jab.
• Storage: Injectable pens typically have cold-chain and refrigeration considerations; a tablet is generally simpler to store and travel with.
• Needle comfort: A tablet removes the injection barrier entirely, which for some people is the deciding factor.

None of these points make one medicine "better" — they make one or the other more suitable for a given person, which is exactly the kind of judgement a prescriber is there to make.

Side effects: a familiar pattern

Because both medicines act on GLP-1 signalling, their side-effect profiles overlap. The most common effects are gastrointestinal — nausea, vomiting, diarrhoea and constipation — and they are usually most noticeable when a dose is first started or stepped up. Slowing the stomach is part of how these medicines curb appetite, so the gut naturally feels the effect too.

Prescribers generally start at a low dose and increase gradually to help the body adjust. You can read more on our side effects page and about the step-up approach on our dosage page. If you experience a side effect from any medicine, you can report it through the MHRA Yellow Card scheme.

Where does UK availability stand?

This is an important part of the Foundayo vs Mounjaro question. Both medicines are now licensed in the UK, but their NHS positions differ. Mounjaro is available on the NHS to a tightly defined group — under NHS England's phased roll-out, GP prescribing is currently limited to people with a BMI of 35 or more (adjusted down for some ethnic backgrounds) plus at least four of five qualifying weight-related conditions — as well as via regulated private providers. Foundayo (orforglipron) was licensed by the MHRA on 10 August 2026 and has been available by private prescription since 24 August 2026; it is not on the NHS, and NICE's appraisal is provisionally expected to publish on 27 January 2027.

We track the latest position on our UK availability page. Whichever medicine is discussed, any legitimate UK supply comes through GPhC-registered pharmacies and CQC-regulated clinics after a prescriber assessment. Avoid websites offering GLP-1 medicines — or "compounded" versions — without a prescription; these fall outside UK regulation and carry real safety risks.

A note on cost

Private prices for GLP-1 treatments vary between regulated providers and change over time. We do not quote prices or name sellers. If cost is a factor, compare regulated UK providers carefully and discuss options with a prescriber or pharmacist.

Frequently asked questions

Related reading

• How orforglipron works: the science behind Foundayo
• Orforglipron trial results: what ATTAIN and ACHIEVE found
• Foundayo dosage schedule: the dose steps month by month